<DOC>
	<DOC>NCT00150592</DOC>
	<brief_summary>The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.</brief_summary>
	<brief_title>Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Subjects with a primary diagnosis of ADHD Minimum baseline visit ADHDRSIV score of 24 and a baseline CGIS score =&gt;4 Male or nonpregnant female subject who agrees to comply with any applicable contraceptive requirements Subject weighs &gt; 55 lbs and is not morbidly overweight Subject has a comorbid psychiatric diagnosis (except ODD) with significant symptoms such as any severe comorbid Axis II disorders or severe Axis I disorders Subject has a history of seizure disorder Subject has any specific cardiac condition or family history of significant cardiac condition Subject is pregnant, lactating or within six month postpartum</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>